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Abstract
Objectives. The objective of our study was to assess hospital variations in the quality of care delivered to acute myocardial inf-
arction (AMI) patients among three Swiss academic medical centres.
Design. Cross-sectional study.
Setting. Three Swiss university hospitals.
Study participants. We selected 1129 eligible patients discharged from these hospitals from 1 January to 31 December 1999,
with a primary or secondary diagnosis code [International Classification of Diseases, 10th revision (ICD-10)] of AMI. We
abstracted medical records for information on demographic characteristics, risk factors, symptoms, and findings at admission.
We also recorded the main ECG and laboratory findings, as well as hospital and discharge management and treatment. We
excluded patients transferred to another hospital and who did not meet the clinical definition of AMI.
Main outcome measures. Percentage of patients receiving appropriate intervention as defined by six quality of care indicators
derived from clinical practical guidelines.
Results. Among 577 eligible patients with AMI in this study, the mean (SD) age was 68.2 (13.9), and 65% were male. In the
assessment of the quality indicators we excluded patients who were not eligible for the procedure. Among cohorts of ‘ideal can-
didates’ for specific interventions, 64% in hospital A and 73% in hospital C had reperfusion within 12 hours either with throm-
bolytics or percutaneous transluminal coronary angioplasty (P = 0.367). Further, in hospitals A, B, and C, respectively 97, 94,
and 84% were prescribed aspirin during the initial hospitalization (P = 0.0002), and respectively 68, 91, and 75% received angio-
tensin converting enzyme inhibitors at discharge in the case of left ventricular systolic dysfunction (P = 0.003).
Conclusions. Our results showed important hospital-to-hospital variations in the quality of care provided to patients with AMI
between these three university hospitals.
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Cardiovascular diseases, among which coronary artery dis-
eases are the most common, are the main cause of death in
middle-aged and older adults in most European countries [1].
Due to its frequency and severity, acute myocardial infarction
(AMI) has been a topic of intense scientific and clinical inter-
est. A series of randomized clinical trials confirmed the effi-
cacy of various therapies, e.g. thrombolysis, beta-blockers,
angiotensin converting enzyme inhibitors [2–5]. From this
evidence, clinical practice guidelines for the management of
patients with AMI have been published [6]. Despite publica-
tion of these guidelines, optimal treatment of patients with
AMI is often not prescribed. In the USA, the Health Care
Financing Administration has implemented, since 1992, a
continuous quality improvement approach to ensure quality
of care for Medicare beneficiaries [7]. Quality indicators (QIs)
were developed from the aforementioned clinical practice
guidelines and several studies were implemented to highlight
differences in patterns of care provided between hospitals
[8,9].
During the same period, several studies have pointed out
geographical variations in the distribution of health care
[10,11]. Some studies have shown geographical variations
among hospitals in the USA regarding the use of cardiac pro-
cedures for AMI patients [12,13]. A recent study showed that
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substantial geographical variations existed in the treatment of
AMI patients across all states in the USA, demonstrating a gap
between knowledge and practice and that therapies of proven
benefit for AMI were underused [13]. In Europe, although few
studies have shown geographical variations [14], a few have
compared process of care in AMI patients within or across
countries [15,16]. Similarly, in Switzerland, some studies have
shown the existing patterns of pharmacological treatment
among AMI patients [17–20]. The objective of our study was
to assess hospital-to-hospital variations in the quality of care of
AMI patients between three Swiss university hospitals.
Methods
Setting and patients
We conducted a cross-sectional study including adult patients
hospitalized for AMI in three Swiss academic medical centres.
These three hospitals were all urban public university hospi-
tals, the major tertiary care centres for their respective areas,
and participated voluntarily in the study. Patients included in
the study were discharged from these hospitals from 1 January
to 31 December 1999, with a primary or a secondary diag-
nosis of AMI [International Classification of Disease, 10th
Revision (ICD-10) codes I21.0–I21.9, I22.0–I22.9, and I23.0–
I23.8]. Cases were identified by means of the mandatory
standardized discharge summary routinely transmitted to the
Swiss Federal Statistical Office.
We found, respectively 553, 380, and 196 eligible patients in
these three hospitals. All 1129 cases were eligible patients regis-
tered in the administrative data system with a primary or sec-
ondary diagnosis of AMI. We excluded 236 patients transferred
to another acute care facility, three patients who left the hospital
against medical advice, four with inconsistent date of discharge,
97 not hospitalized for an AMI but actually coded so, and 70
patients with an incomplete or missing chart. We further
excluded 142 cases because the considered episode did not
match the clinical definition of AMI, using the definition
described in the consensus document of the Joint European
Society of Cardiology/American College of Cardiology Com-
mittee for the Redefinition of Myocardial Infarction. This defi-
nition includes typical rises or gradual falls (troponin) or more
rapid rises or falls (CK-MB) of biochemical markers of myocar-
dial necrosis with at least one of the following: (i) ischaemic
symptoms; (ii) development of pathologic Q-waves on the
ECG; (iii) ECG changes as indicative of ischaemia (ST-segment
elevation or depression) [21]. The final sample size was 577.
Data
Data abstraction was conducted by trained medical doctors or
medical record specialists. In two hospitals, the entire medical
charts were available for data abstraction. In the third, only
the electronic medical records, which included the discharge
letter, laboratory results, and all cardiological procedures,
were obtained. Variables abstracted from the charts included age,
sex, smoking status, hypertension, diabetes, hyperlipidaemia,
history of heart failure, stroke, angina pectoris, or myocardial
infarction. Clinical information included measurement of
chest pain, syncope, dyspnoea, and cardiogenic shock. We
also recorded ECG findings and laboratory values, as well as,
if available, the ejection fraction or a narrative description of
the ejection fraction on an echocardiography, angiography, or
ventriculography. We also abstracted medication at admission
(including thrombolysis), during hospitalization, and at dis-
charge as well as specific procedures such as percutaneous
transluminal coronary angioplasty and coronary artery bypass
surgery. The Charlson co-morbidity index, a weighted average
of selected comorbidities, was computed at index hospitaliza-
tion for each patient as measurement of severity of illness,
using the Deyo modification [22].
QIs
QIs were developed from evidence-based guidelines. They
were derived from the US Cooperative Cardiovascular
Project [8,9] and used in many studies. The development of
these performance measurements for AMI was based on the
reliability and validity of the indicator and on the evidence of
a process–outcome link [23]. They were adapted locally with
key clinicians. Table 1 summarizes these QIs with the respec-
tive exclusion criteria.
The first QI was the measurement of timely reperfusion
within 12 hours of admission by use of thrombolytics or percu-
taneous transluminal coronary angioplasty. Patients who were
treated only with thrombolytics (no percutaneous transluminal
coronary angioplasty) were excluded if they had a contraindica-
tion to thrombolytics. We abstracted the time in minutes
between the admission and the procedure. The second and
third QIs were the prescription of aspirin, respectively within
24 hours after admission, and at discharge. We excluded
patients with contraindications to aspirin. For all QIs related to
a prescription or counselling at discharge, we excluded patients
who died at the hospital. The fourth QI was the prescription of
β-blockers at discharge. All β-blockers prescribed at discharge
were recorded and patients with contraindication were
excluded. The fifth QI was prescription of angiotensin convert-
ing enzyme inhibitors at discharge in patients with left ventricu-
lar systolic dysfunction, which was defined as a value of the
ejection fraction of ≤40% documented in the chart from the
current hospitalization. If no quantified information was found
in the chart, a patient was classified as having left ventricular
systolic dysfunction based on narrative terms describing the
ejection fraction. Angiotensin converting enzyme inhibitors
were identified in the medical charts through generic or trade
name. We excluded from the study patients who experienced
any of the listed contraindications to angiotensin converting
enzyme inhibitors. We assessed smoking cessation counselling
with the information available in the medical record.
Analysis
Firstly, descriptive univariate measures were implemented.
Then, bivariate analyses were conducted using when appro-
priate χ2 tests, Fisher’s exact tests, and analysis of variance
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(ANOVA) methods. No adjusted analyses are reported since
all eligible patients should be considered for the procedures
examined. All analyses were conducted with SAS software,
version 8.02 (SAS institute Inc., Cary, NC, USA).
Results
Of the 577 eligible patients, 216 (37.4%) were hospitalized
in hospital A, 270 (46.8%) in hospital B, and 91 (15.8%) in
hospital C. The mean (SD) age of the entire sample was
68.2 (13.9) years, 65.2% were male, 12.6% had a previous
history of heart failure, 35.5% a previous AMI or history
of angina, 6.5% a previous stroke, 55.2% hypertension,
67.8% hyperlipidaemia, 22.8% diabetes, and 31.5% were
current smokers.
Patient characteristics by hospital
Patient characteristics at admission are reported in Table 2 for
each hospital. The mean age was slightly higher in hospital B
compared with the other providers. More males were hospi-
talized in hospital C compared with hospitals A and B. Simi-
larly, more patients were hospitalized in hospital C with a
previous AMI or angina, compared with hospitals A and B.
We also observed that more patients were hospitalized with
hyperlipidaemia in hospital B, compared with other provid-
ers. We noted that in hospital C chest pain was less frequent
but a cardiogenic choc occurred more often. In hospital C,
20.9% of the patients had coronary artery bypass surgery dur-
ing hospitalization, compared with 12.2% in hospital B, and
7.4% in hospital A.
QIs across hospitals
A review of QIs is reported in Table 3. Reperfusion within 12
hours with thrombolytics or primary percutaneous translumi-
nal coronary angioplasty was performed in 66.2% of AMI
patients, and, respectively, 64.3% and 72.7% in hospitals A
and C (information not available in hospital B). Large varia-
tions were observed between hospitals for the prescription of
aspirin within 24 hours after admission in patients with no
contraindication to aspirin. In hospital B, 97.2% of eligible
patients received aspirin within 24 hours of admission, com-
pared with 94.4% in hospital B, and 84.6% in hospital C. At
discharge, 91.0% of the patients with no contraindication
received aspirin, and 80.5% β-blockers. Less variation
between hospitals was observed for these two QIs. However,
large variation was observed for the prescription of angio-
tensin converting enzyme inhibitors at discharge for patients
with left ventricular systolic dysfunction and no contraindica-
tion to angiotensin converting enzyme inhibitors. In hospital
Table 1 Quality indicators for the diagnosis and management of acute myocardial infarction
Quality indicator Description
... .......................................................................................................................................................................................................................
1 Receipt of reperfusion (within 12 hours) 
either with thrombolytics or primary 
percutaneous transluminal coronary 
angioplasty (PTCA)
Proportion of patients receiving thrombolytics or undergoing primary
PTCA during the first 12 hours of their arrival at hospital. 
Exclusions: patients who had only thrombolysis (no PTCA) were excluded if 
they had one of the following contraindications to thrombolysis: bleeding, 
chronic hepatic disease, coagulopathy, gastric ulcer, recent stroke, recent 
surgery or trauma, resuscitation within 6 hours.
2 Aspirin within 24 hours Frequency of patients receiving aspirin during the first 24 hours.
Exclusions: patients with recent bleeding, chronic hepatic disease, 
coagulopathy, gastric ulcer, anticoagulants at admission, metastatic or 
terminal cancer, allergy to aspirin.
3 Aspirin at discharge Frequency of use of aspirin at discharge in patients discharged alive.
Exclusions: patients with recent bleeding, chronic hepatic disease, 
coagulopathy, gastric ulcer, anticoagulants at admission, metastatic or 
terminal cancer, allergy to aspirin.
4 β-blockers at discharge Frequency of use of β-blockers at discharge in patients discharged alive.
Exclusions: patients with hypotension or shock, or systolic blood pressure 
< 100 mmHg, asthma, chronic obstructive pulmonary disease, bradycardia, 
dementia, bi-fascicular or tri-fascicular block, severe heart failure with 
pulmonary oedema, or New York Heart Association Class IV.
5 Angiotensin converting enzyme 
inhibitors (ACEIs) at discharge if left 
ventricular systolic dysfunction
Frequency of use of ACEIs at discharge in patients with reduced left 
ventricular function (ejection fraction ≤ 40%).
Exclusions: patients with cough, renal insufficiency, skin rash, hyperkalaemia, 
angio-oedema, neutropenia, and hypotension related to ACEI use.
6 Smoking cessation counselling Frequency of smoking cessation counselling in cigarette smokers during 
hospitalization.
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Table 2 Demographic characteristics, risk factors, symptoms, and findings at admission in patients with AMI, by hospital, n = 577
SD, standard deviation; HF, heart failure; AMI, acute myocardial infarction.
Characteristics n (%) or 
mean (SD)
Hospital A, 
n (%) or mean 
(SD), n = 216
Hospital B, 
n (%) or mean 
(SD), n = 270
Hospital C, 
n (%) or mean 
(SD), n = 91
P value
.........................................................................................................................................................................................................................
Age
Mean (SD) 68.2 (13.9) 68.0 (14.1) 69.5 (13.6) 64.8 (13.9) 0.018
16–60 years 171 (29.6) 67 (31.0) 74 (27.4) 30 (33.0) 0.059
61–70 years 140 (24.3) 50 (23.2) 58 (21.5) 32 (35.2)
71–80 years 137 (23.7) 49 (22.7) 72 (26.7) 16 (17.6)
>80 years 129 (22.4) 50 (23.2) 66 (24.4) 13 (14.3)
Sex
Male 376 (65.2) 132 (61.1) 175 (64.8) 69 (75.8) 0.047
Female 201 (34.8) 84 (38.9) 95 (35.2) 22 (24.2)
Previous history HF (n = 538) 68 (12.6) 23 (11.1) 32 (13.3) 13 (14.29) 0.682
Previous AMI or angina (n = 564) 200 (35.5) 68 (32.2) 82 (31.3) 50 (55.0) 0.0001
Previous stroke (n = 570) 37 (6.5) 15 (7.0) 16 (6.0) 6 (6.6) 0.911
Hypertension (n = 569) 314 (55.2) 125 (59.0) 143 (53.6) 46 (51.1) 0.348
Hyperlipidaemia (n = 503) 341 (67.8) 145 (69.1) 150 (72.5) 46 (53.5) 0.006
Diabetes (n = 570) 130 (22.8) 40 (18.8) 65 (24.3) 25 (28.1) 0.158
Current smoker (n = 569) 179 (31.5) 70 (32.7) 74 (27.8) 35 (39.3) 0.114
Symptoms and findings
Chest pain (n = 564) 468 (83.0) 189 (89.6) 222 (84.7) 57 (62.6) <0.0001
Syncope (n = 570) 58 (10.2) 17 (7.9) 27 (10.2) 14 (15.4) 0.141
Dyspnoea (n = 564) 189 (33.5) 75 (34.9) 75 (29.1) 39 (42.9) 0.049
Cardiogenic shock (n = 568) 67 (11.8) 23 (10.8) 21 (7.8) 23 (26.4) <0.0001
Mean (SD) Charlson comorbidity
index (n = 577)
1.6 (1.4) 1.9 (1.2) 1.9 (1.4) 0.1 (0.3) <0.0001
Mean (SD) length of stay 
(n = 577)
12.9 (12.7) 12.6 (10.2) 14.5 (14.9) 8.5 (9.2) 0.0004
Median length of stay 10.0 10.5 9.0 6.0
Table 3 Quality Indicators in patients with acute myocardial infarction by hospital, n = 577
PTCA, percutaneous transluminal coronary angioplasty; ACEIs, angiotensin converting enzyme inhibitors; LVSD, left ventricular systolic
dysfunction; NA, not applicable because the information about the exact time in minutes of PTCA was not available.
Indicators Total 
(n = 577), n (%)
Hospital A 
(n = 216), n (%)
Hospital B 
(n = 270), n (%)
Hospital C 
(n = 91), n (%)
P value
.............................................................................................................................................................................................................................
Quality indicators
Receipt of reperfusion 
(within 12 hours) either 
with thrombolytics 
or primary PTCA (n = 145)
96 (66.2) 72 (64.3) (n = 112) NA 24 (72.7) (n = 33) 0.367
Aspirin within 24 hours (n = 532) 499 (93.8) 205 (97.2) (n = 211) 217 (94.4) (n = 230) 77 (84.6) (n = 91) 0.0002
Aspirin at discharge (n = 478) 435 (91.0) 168 (94.4) (n = 178) 207 (89.6) (n = 231) 60 (87.0) (n = 69) 0.110
β-Blockers at discharge (n = 400) 322 (80.5) 113 (78.5) (n = 144) 154 (79.4) (n = 194) 55 (88.7) (n = 62) 0.203
ACEIs at discharge if LVSD 
(n = 154)
122 (79.2) 46 (67.6) (n = 68) 67 (90.5) (n = 74) 9 (75.0) (n = 12) 0.003
Smoking cessation advice 
(n = 158)
68 (43.0) 32 (50.8) (n = 63) 31 (50.8) (n = 61) 5 (14.7) (n = 34) 0.0008
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B, 90.5% of the patients received angiotensin converting
enzyme inhibitors, compared with 75.0% in hospital C, and
67.7% in hospital A.
Discussion
This study indicates that substantial variations existed between
these three Swiss academic medical centres regarding the
management and treatment of AMI patients. Furthermore, our
results indicate that most patients received appropriate care,
based on European or US standards. Our finding that reper-
fusion within 12 hours with thrombolytics or primary percuta-
neous transluminal coronary angioplasty was performed in
66.2% of patients, was similar to the results of a study among
Medicare patients including all acute care hospitals in the USA.
In that study, conducted in 1995, 68.7% of the patients hospi-
talized with AMI had reperfusion within 12 hours [8]. Another
publication from the Medicare Healthcare Improvement
Program showed a slight increase in reperfusion therapy in all
US hospitals, from 59.2% in 1994–1995 to 60.6% for the
period 1998–1999 [24]. This study showed that the manage-
ment of AMI patients in the acute phase has improved over the
years in the USA, especially regarding early reperfusion.
However, aspirin prescription rates, within 24 hours of
admission and at discharge, showed higher figures in our study
compared with published US rates, which were 85% and 86%
for the years 1998–1999 and 2000–2001, respectively [9,24].
During the same period, 79% of the patients received aspirin at
discharge in one Swiss academic medical centre [18].
Concerning the prescription of β-blockers at discharge, our
results are comparable with those described in the USA in
2000–2001 (79%) [9], but we implemented our study in 1999.
Our results are higher than those found in a study conducted
in one Swiss university hospital in 1996, where 70% of the
patients with no contraindication received β-blockers [18]. For
the prescription of angiotensin converting enzyme inhibitors
at discharge in case of left ventricular systolic dysfunction,
our results are also similar to those observed in the USA for
the years 2000 and 2001 [9].
Over the past few decades, the importance of variation in
modern medicine has been demonstrated. In particular, dif-
ferences have been observed in the way similar patients are
treated in one health care setting compared with another [25].
John Wennberg was a pioneer in this field and his research
findings about small area variations in New England are
reported [11,26].
Variations in health care management and delivery have
been demonstrated previously for the use of cardiac proce-
dures after AMI [12,13]. One study focused on whether or
not geographical variations in the use of health services were
due to inappropriate care. They studied the appropriateness
of the use of coronary angiography and carotid endarterec-
tomy. They found only small differences in the levels of
appropriateness for these procedures between geographical
areas of high, average, and low use. They concluded that dif-
ferences in appropriateness could not explain geographical
variations in the use of these procedures [27].
Several limitations may have biased our results. Firstly, in
Switzerland administrative discharge data have been manda-
tory since 1998. The quality of data has improved but is still
very heterogeneous across providers. In particular, only 196
eligible AMI patients were identified through ICD-10 codes
in one hospital, which is about the same size as the two others
included in the study, from where twice the number of
patients was recorded. A selection bias may have occurred
because of this lower figure in the identification of AMI
patients in one hospital. Another limitation is related to the
chart abstraction process, which was conducted in each hos-
pital by different people, with various educational back-
grounds, although their training, and reporting procedures
were similar. Furthermore, in two of the hospitals, the entire
medical chart was obtained by the abstractors, whereas in the
third, only the electronic discharge letter, laboratory findings
and reports from cardiology testing were available. In addi-
tion, the quality of medical records and completeness of
information may also vary within and between centres. Incor-
rect information may have brought some misclassification
bias. Another limitation was the fact that hospital participa-
tion in this study was voluntary. Representation could differ
considerably between these voluntary hospitals and other
hospitals, making the generalization of results questionable.
In conclusion, we found significant hospital-to-hospital
variation in the quality of care delivered to AMI patients
between three Swiss academic medical centres. We believe
that these variations are unlikely to be fully explained by sys-
tematic errors and are therefore at least partially real. Our
findings indicate that, according to the published evidence of
effectiveness, the management and treatment of AMI patients
could be improved, although it was comparable to the
observed quality of care delivered in other European or US
hospitals.
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